Led · Equity · Apr 2026

TIBEAY Biosciences is a clinical-stage biotechnology company based in the Netherlands focused on developing innovative therapies for acute neurological diseases. Its lead candidate, Ronopterin, is described as a first-in-class inhibitor of inducible nitric oxide synthase (iNOS) intended to reduce secondary brain damage after severe traumatic brain injury (SHT). The company plans a European multicenter Phase 3b study and aims to submit a marketing authorization application to the EMA based on that trial. The recently completed €35 million financing will fund the Phase 3b study, production of the investigational product, supply-chain activities, and regulatory and operational preparations for potential approval. TIBEAY is engaging investors including Münchner Athos KG, MIG Fonds, Meneldor and Oost NL to support its clinical and regulatory programs. The company positions Ronopterin as targeting an unmet medical need where no approved pharmacologic therapies currently exist.

Led · Series C · Jan 2026

Antheia is a biosynthesis company focused on transforming pharmaceutical manufacturing through engineered microorganisms that produce complex active pharmaceutical ingredients (APIs). The firm employs its advanced biosynthesis platform to generate critical drug ingredients domestically, reducing reliance on fragile global supply chains. Under an ongoing collaboration with the U.S. government’s BioMaP-Consortium, Antheia will scale commercial production of two essential pharmaceutical compounds in the United States. The company positions its technology as a solution to longstanding vulnerabilities in healthcare supply chains and aims to build a more resilient, on-shore source of medicines for the American market. To date, Antheia has secured $21 million in federal project investment dedicated to this initiative, including a recent $9 million expansion award. These funds will be deployed to increase manufacturing capacity and accelerate the company’s path to large-scale commercialization. No additional operating metrics or revenue figures were disclosed in the article.

Participated · Series B · Jan 2026

Bactolife is a Danish startup creating a new class of gut-health ingredients called binding proteins that latch onto and flush out harmful bacterial metabolites without disrupting the microbiome. Drawing inspiration from camelid immunoglobulin fragments, the firm engineers microbes via precision fermentation to produce vegan, allergen-free, heat- and pH-stable proteins effective at 100–200 mg doses. Its first two proteins are expected to receive self-affirmed GRAS status in the U.S. in Q1 and will debut this year under the “Helm” brand in dietary supplements and functional foods, with subsequent rollouts planned for Asia and Europe. The company is running human clinical studies in the U.S. and U.K. and has already secured several commercial partners interested in standalone or combined formulations with pre- and probiotics. Over the next three to five years, Bactolife intends to build a broad portfolio of binding proteins addressing common gut-health concerns and to supply both human nutrition and animal feed markets. A recently raised €30 million+ ($35 million+) Series B round will finance clinical validation, regulatory filings, manufacturing scale-up and commercialization. The article did not disclose any current revenue or user metrics.

Led · Equity · Sep 2025

AMSilk develops advanced biomaterials from silk-based proteins using a patented technology platform and a supporting patent portfolio. It converts man-made proteins into formulations including fibers and yarns, hydrogels, and silk powder. The company’s high-performance materials target applications across the textile, homecare, biomedical, and automobile industries. AMSilk has collaborated with global companies and intends to continue partnering with enterprises worldwide. The company plans to use the new funds to build further commercial traction and to support the next phase of industrial scale-up to meet growing global demand. The raise followed an extension of its Series C financing in 2023. AMSilk produces bio-fabricated silk protein materials using a patented biotechnological process, converting plant-based renewable inputs into powders, hydrogels, fibers, and coatings. Its materials are 100% protein, do not involve natural farming processes, and are fully biodegradable under aerobic and marine conditions without generating microplastics. The company plans to use the new funding to accelerate industrial scale-up and expand commercial operations for its biotech materials. AMSilk raised an additional €25M in a Series C extension, bringing the total Series C to €54M. The extension was led by ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital. Since a €29M financing in 2021, AMSilk has invested in partnership agreements and supply contracts with leading apparel, medical, automotive, and biotech companies. AMSilk is an industrial supplier of synthetic silk biopolymers based in Planegg, near Munich, Germany. Its products are produced from plant-based raw material via bacterial fermentation and possess mechanical and biochemical properties suitable for multiple industries. The company offers high-performance Biosteel® fibers for textiles and industrial applications worldwide and cites use cases in medical devices and personal care products. AMSilk has announced collaborations and partnerships with brands like Adidas and Airbus. Led by CEO Ulrich Scherbel, the company plans to accelerate scale-up of its industrial projects and internationalize commercial activities to expand its customer base into new markets. It raised €29M in a Series C round to fund these efforts. AMSilk produces and processes SPIDERSILK biopolymers copied from the proteins of web-weaving spiders. These biopolymers enable new technical products and improvements to existing products. According to the company, the materials offer mechanical toughness, chemical resistance and biocompatibility while being completely biodegradable. AMSilk completed a €5m Series B financing and intends to use the capital to expand development and sales efforts for its first spider silk-based products. The company plans to pursue those efforts through partnerships with leading companies across major industries. Founded in 2008 as a spin-off from the Technische Universität München, AMSilk is led by Managing Director Axel Leimer.

Participated · Series B · Sep 2025

MRM Health develops microbiome-based biotherapeutic products using its proprietary CORAL® platform to assemble and produce disease-specific microbial consortia. The company is advancing its lead program MH002 into clinical development for ulcerative colitis and the rare condition pouchitis, while running preclinical programs in other inflammatory indications and immuno-oncology. MRM Health recently completed a €55 million Series B in September 2025 led by Biocodex with participation from ATHOS, BNP Paribas Fortis Private Equity and existing investors SFPIM, AvH, OMX Venture, QBic and VIB. The €2.6 million VLAIO grant will fund a three-year collaborative research program with Belgian academic partners to generate mechanistic and clinical microbiome data and accelerate LBP candidate development toward clinical proof-of-concept. The company is headquartered in Ghent, Belgium and reports products in clinical stages.